TITLE

Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye

AUTHOR(S)
Natarajan, Jayaganesh V.; Ang, Marcus; Darwitan, Anastasia; Chattopadhyay, Sujay; Wong, Tina T.; Venkatraman, Subbu S.
PUB. DATE
January 2012
SOURCE
International Journal of Nanomedicine;2012, Vol. 7, p123
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
82508791

 

Related Articles

  • Novel drug delivery systems will target better glaucoma treatment. Caceres, Vanessa // Ophthalmology Times;Jan2016, Vol. 41 Issue 1, p19 

    The article suggests that until glaucoma drug delivery methods beyond eye drops are developed and made available, clinicians must coach patients on better drop use and teach healthcare payers about the importance of compliance. Topics include drawback of eye drops as well as novel drug delivery...

  • Sustained Release of an Anti-Glaucoma Drug: Demonstration of Efficacy of a Liposomal Formulation in the Rabbit Eye. Natarajan, Jayaganesh V.; Chattopadhyay, Sujay; Ang, Marcus; Darwitan, Anastasia; Foo, Selin; Zhen, Ma; Koo, Magdalene; Wong, Tina T.; Venkatraman, Subbu S. // PLoS ONE;2011, Vol. 6 Issue 9, p1 

    Topical medication remains the first line treatment of glaucoma; however, sustained ocular drug delivery via topical administration is difficult to achieve. Most drugs have poor penetration due to the multiple physiological barriers of the eye and are rapidly cleared if applied topically....

  • Future of therapy looks bright. Groves, Nancy; Fingeret, Murray // Optometry Times;Apr2012, Vol. 4 Issue 4, p23 

    The article discusses some developments in treating glaucoma. Medical therapy remains the mainstay for treating glaucoma with the introduction of preservative-free prostaglandin analog including tafluprost and dorzolamide and the release of generic versions of latanoprost. In the field of drug...

  • Frequently asked questions about latanoprost. Camras, Carl B. // Ophthalmology Times;12/01/97, Vol. 22 Issue 23, p7 

    Part II. Provides answers to questions on the glaucoma medication, latanoprost. Effectivity of latanoprost in several types of glaucoma; Latanoprost with nonsteroidal anti-inflammatory drugs; Stability of latanoprost; When to use the medication in glaucoma therapy.

  • Xalatan.  // Royal Society of Medicine: Medicines;2002, p571 

    This article provides information on Xalatan, a proprietary, prescription-only preparation of the prostaglandin analogue latanoprost. It can be used as a glaucoma treatment in open-angle glaucoma and ocular hypertension. It is available as eye-drops.

  • Latanoprost effective as first-line or add on therapy. Vinals, Antonio F. // Ophthalmology Times;02/15/98, Vol. 23 Issue 4, p32 

    Investigates the efficacy of Latanoprost as additional or replacement therapy in eyes with uncontrolled glaucoma. Details on the study using the medication; Complications on the use of Latanoprost; Limitations and conclusion of the study.

  • Latanoprost. Ritch, Robert // Ophthalmology Times;11/1/96, Vol. 21 Issue 27, Eye to Eye p2 

    Provides information about latanoprost, a drug used to treat glaucoma. Food and Drug Administration approval of drug marketed under the name `Xalatan'; Side effects; Impact of drug in addition to that of all other classes of antiglaucoma medications; Capacity of latanoprost to change eye color.

  • Xalacom.  // Royal Society of Medicine: Medicines;2002, p571 

    This article provides information on Xalacom, a proprietary prescription-only preparation of the prostaglandin analogue latanoprost with the beta-blocker timolol. It can be used as a glaucoma treatment in open-angle glaucoma and ocular hypertension. It is available as eye-drops.

  • Iris pigmentation changes monitored with glaucoma therapy. Charters, Lynda // Ophthalmology Times;2/1/2005, Vol. 30 Issue 3, p22 

    The article reports that adjunctive latanoprost therapy for open-angle glaucoma is safe and effective. It is based on the results of a 5 year assessment of the drug. The mean decrease in intraocular pressure (IOP) was 25 percent of the baseline IOP and this was sustained without any treatment...

  • New sight. Wolfe, Yun Lee // Prevention;Mar97, Vol. 49 Issue 3, p46 

    Looks at treatment options for glaucoma as of March 1997. New medication called latanoprost for treating glaucoma; Statistics on the number of Americans affected by glaucoma; Study of latanoprost on eye pressure; Report published in `Opthalmology,' January 1996 and `Archives of Opthamology,'...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics